Cell Proliferation in Colorectal Adenocarcinomas: Comparison Between Ki-67 Immunostaining and Bromodeoxyuridine Uptake Detected by Immunohistochemistry and Flow Cytometry

Pessot, Florence Le; Michel, Pierre; Paresy, Marianne; Lemoine, F; Hellot, Marie‐France; Scotté, Michel; Peillon, Christophe; Hémet, J

doi:10.1078/0344-0338-00054

Cited by 5 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wilson et al showed that while IUdR assessed by FCM (IUdRfmc) and assessed by IHC (IUdRimm) correlated with each other, and their LIs were significantly higher in aneuploid than diploid tumors, no prognostic property of these markers was demonstrated [ 124 ]. Similar results were reported by other authors [ 126 ]. On the other hand, Palmqvist et al, using both IUdR detection techniques (FCM + IHC), demonstrated that patients with Dukes’ B tumors with higher IUdR LI (in invasive margin) and/or low Tpot (at both the invasive margin and the luminal border) had longer survival [ 100 ].…”

Section: Methods To Assess Cell Proliferation In Colorectal Cancersupporting

confidence: 93%

“…DNA content and ploidy were evaluated as prognostic factors in CRC [ 123 , 124 , 125 , 126 ], with DNA aneuploidy demonstrated to be a feature of tumors with a higher proliferation rate [ 124 , 126 , 127 ]. On the other hand, ploidy alone, determined by flow cytometry (FCM), had no prognostic significance in CRC (DFS).…”

Section: Methods To Assess Cell Proliferation In Colorectal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Biomarkers of Cell Proliferation in Colorectal Cancer (CRC): From Immunohistochemistry to Molecular Biology Techniques

Kasprzak

2023

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common and severe malignancies worldwide. Recent advances in diagnostic methods allow for more accurate identification and detection of several molecular biomarkers associated with this cancer. Nonetheless, non-invasive and effective prognostic and predictive testing in CRC patients remains challenging. Classical prognostic genetic markers comprise mutations in several genes (e.g., APC, KRAS/BRAF, TGF-β, and TP53). Furthermore, CIN and MSI serve as chromosomal markers, while epigenetic markers include CIMP and many other candidates such as SERP, p14, p16, LINE-1, and RASSF1A. The number of proliferation-related long non-coding RNAs (e.g., SNHG1, SNHG6, MALAT-1, CRNDE) and microRNAs (e.g., miR-20a, miR-21, miR-143, miR-145, miR-181a/b) that could serve as potential CRC markers has also steadily increased in recent years. Among the immunohistochemical (IHC) proliferative markers, the prognostic value regarding the patients’ overall survival (OS) or disease-free survival (DFS) has been confirmed for thymidylate synthase (TS), cyclin B1, cyclin D1, proliferating cell nuclear antigen (PCNA), and Ki-67. In most cases, the overexpression of these markers in tissues was related to worse OS and DFS. However, slowly proliferating cells should also be considered in CRC therapy (especially radiotherapy) as they could represent a reservoir from which cells are recruited to replenish the rapidly proliferating population in response to cell-damaging factors. Considering the above, the aim of this article is to review the most common proliferative markers assessed using various methods including IHC and selected molecular biology techniques (e.g., qRT-PCR, in situ hybridization, RNA/DNA sequencing, next-generation sequencing) as prognostic and predictive markers in CRC.

show abstract

Section: Methods To Assess Cell Proliferation In Colorectal Cancersupporting

confidence: 93%

Section: Methods To Assess Cell Proliferation In Colorectal Cancermentioning

confidence: 99%

Prognostic Biomarkers of Cell Proliferation in Colorectal Cancer (CRC): From Immunohistochemistry to Molecular Biology Techniques

Kasprzak

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Ki67 is a prototypic cell-cycle-related nuclear protein, expressed by proliferating cells in all active phases of the cell cycle (G1, S, G2, and M phases), but it is absent in the resting G0 phase (35). It was proven that Ki67 functions as a growth fraction marker, offering a good representation of proliferation status (36, 37). The Ki67 assay showed that the percentage of Ki67+ cells was higher when RPE cells were cultured with 100 µg/mL PSPA for 2 days (Fig.…”

Section: Resultsmentioning

confidence: 99%

The influences of purple sweet potato anthocyanin on the growth characteristics of human retinal pigment epithelial cells

Sun

Lü

Lei

et al. 2015

Food & Nutrition Research

View full text Add to dashboard Cite

BackgroundAnthocyanins have been proven to be beneficial to the eyes. However, information is scarce about the effects of purple sweet potato (Ipomoea batatas, L.) anthocyanin (PSPA), a class of anthocyanins derived from purple sweet potato roots, on visual health.ObjectiveThe aim of this study was to investigate whether PSPA could have influences on the growth characteristics (cellular morphology, survival, and proliferation) of human retinal pigment epithelial (RPE) cells, which perform essential functions for the visual process.MethodsThe RPE cell line D407 was used in the present study. The cytotoxicity of PSPA was assessed by MTT assay. Then, cellular morphology, viability, cell cycle, Ki67expression, and PI3K/MAPK activation of RPE cells treated with PSPA were determined.ResultsPSPA exhibited dose-dependent promotion of RPE cell proliferation at concentrations ranging from 10 to 1,000 µg/ml. RPE cells treated with PSPA demonstrated a predominantly polygonal morphology in a mosaic arrangement, and colony-like cells displayed numerous short apical microvilli and typical ultrastructure. PSPA treatment also resulted in a better platform growing status, statistically higher viability, an increase in the S-phase, and more Ki67+ cells. However, neither pAkt nor pERK were detected in either group.ConclusionsWe found that PSPA maintained high cell viability, boosted DNA synthesis, and preserved a high percentage of continuously cycling cells to promote cell survival and division without changing cell morphology. This paper lays the foundation for further research about the damage-protective activities of PSPA on RPE cells or human vision.

show abstract

“…A similar discrepancy was recently found in human gastric tissue between in vivo Iododeoxyuridine labelling and Ki‐67 LI (determined with MIB‐1), with a fair correlation (r=0.63) in normal mucosa and absence of such a correlation in gastric carcinoma (40). Also, in human colon cancer (41) and breast cancer (34) the correlation between in vivo BrdU labelling and Ki‐67 staining was found to be only modest (r=0.45 and 0.44, respectively).…”

Section: Discussionmentioning

confidence: 99%

Validation of the use of proliferation markers in canine neoplastic and non‐neoplastic tissues: comparison of KI‐67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labelling by immunohistochemistry

Zacchetti¹,

Garderen²,

Teske

et al. 2003

APMIS

View full text Add to dashboard Cite

In order to evaluate the suitability of Ki-67 and proliferating cell nuclear antigen (PCNA) for determination of proliferative activity, the immunohistochemically determined nuclear expression of these antigens in canine non-neoplastic and neoplastic tissues was compared with the results of in vivo bromodeoxyuridine (BrdU) labelling, which - by measurement of the fraction of S-phase cells - is considered as the standard in the analysis of proliferative activity. The samples investigated consisted of non-neoplastic mammary and lymphoid tissues, and of benign and malignant (primary/metastatic) mammary tumours, and malignant lymphomas. Great regional heterogeneity prevented determination of an overall labelling index (LI) in normal lymphoid tissues. In the remaining combined group of samples, LI values were significantly ranked in the order PCNA>Ki-67>BrdU. However, the correlation of Ki-67 or PCNA as compared to BrdU LI values was only moderate in the combined group [approximately 0.5, Spearman rank test] as well as in most subgroups, whilst it was very poor in the group of primary mammary cancers. These observations indicate that Ki-67 or PCNA LIs as markers of proliferation do not evenly match in vivo BrdU labelling.

show abstract

Cell Proliferation in Colorectal Adenocarcinomas: Comparison Between Ki-67 Immunostaining and Bromodeoxyuridine Uptake Detected by Immunohistochemistry and Flow Cytometry

Cited by 5 publications

References 24 publications

Prognostic Biomarkers of Cell Proliferation in Colorectal Cancer (CRC): From Immunohistochemistry to Molecular Biology Techniques

Prognostic Biomarkers of Cell Proliferation in Colorectal Cancer (CRC): From Immunohistochemistry to Molecular Biology Techniques

The influences of purple sweet potato anthocyanin on the growth characteristics of human retinal pigment epithelial cells

Validation of the use of proliferation markers in canine neoplastic and non‐neoplastic tissues: comparison of KI‐67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labelling by immunohistochemistry

Contact Info

Product

Resources

About